首页/数据集/Supplementary Table S5 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs

Supplementary Table S5 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs

NIAID Data Ecosystem2026-04-30 收录

肿瘤耐药机制

靶向药物研发

数据链接：

https://figshare.com/articles/dataset/Supplementary_Table_S5_from_ER-851_a_Novel_Selective_Inhibitor_of_AXL_Overcomes_Resistance_to_Antimitotic_Drugs/22523430 数据链接链接失效反馈

官方服务：

资源简介：

Supplementary Data Table S5

应用场景：

创建时间：

2023-01-03

肿瘤耐药机制

组合治疗

EGFR-mut NSCLC lines show differential suceptibility to inhibition of tankyrase in the presence of EGFR inhibitors Overall design: NSCLC cells were treated in quadruplicate with gefitinib, AZ1366 (tan

NIAID Data Ecosystem80

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

肿瘤耐药机制

信号通路靶向治疗

BackgroundThe sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAFV600 mutant melanoma is limited primarily by the development of acquired resistance le

Figshare2016-01-18 更新50

NLRC4 promotes PANoptosis to overcome sorafenib resistance in hepatocellular carcinoma by competitively binding to BCLAF1 with TRIB3

肿瘤耐药机制

细胞死亡调控

Objective: Hepatocellular carcinoma (HCC) is a leading global cause of cancer death with poor prognosis. Sorafenib is the therapeutic agent for HCC, but its clinical efficacy is severely compromised b

国家人口健康科学数据中心40

Identification of M4205 a highly selective inhibitor of cKIT mutations for unresectable metastatic or recurrent GIST

靶向药物研发

cKIT抑制剂

Identification of M4205 a highly selective inhibitor of cKIT mutations for unresectable metastatic or recurrent GIST Descriptor: 5-imidazo[1,2-a]pyridin-3-yl-~{N}-[(1~{R})-1-(6-pyrrolidin-1-ylpyridin-

Protein Data Bank Japan2024-02-07 更新60

Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]. Homo sapiens

肿瘤耐药机制

转录组药物响应

Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types

NIAID Data Ecosystem50

Supplementary Table S5 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs

资源简介：

相关数据集